HIPEC / CRS-HIPEC (Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy)
Oncology
Daga
$15,000
Har zuwa $45,000 ya danganta da cibiya
Tsawon lokaci na yau da kullum
21–45 days
Hada da gwaje-gwajen kafin tiyata
An bincika wannan abun ciki don daidaiton likitanci daga: Dr. Rodina Ainasoa · Marubuciyar Likitanci & Sadarwar Lafiya
Bayyani
A two-step surgical oncology treatment for peritoneal surface malignancies — cytoreductive surgery (CRS) to remove all visible tumour from the abdominal cavity, followed immediately by heated chemotherapy circulated directly within the abdomen (HIPEC) to destroy remaining microscopic disease. Used for peritoneal carcinomatosis arising from colorectal, appendiceal, ovarian, and gastric cancers, and pseudomyxoma peritonei.
Ana daidaita al'amarinku da cibiya bisa bayanan sakamako na likitanci, ba talla ba. Muna tsara kowane mataki — daga gwaje-gwajen kafin tiyata zuwa biye-biye bayan jiyya — tare da mai tsara kulawa na musamman.
Abinda ya hada
HIPEC / CRS-HIPEC (Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy)
An tsara daga
ko aiko mana sako a kan WhatsApp
Ba a bukatar alkawari. Ba a taba raba bayananku da wasu jam'iyyu ba.
Wa ne ya cancanci CRS-HIPEC?
An kebe CRS-HIPEC ga marasa lafiya masu ciwon daji na uwar peritoneal inda cirewa cikakke ko kusan cikakke na ciwon daji mai ganuwa zai yiwu a zahiri. Ana tantance cancanta ta amfani da Peritoneal Carcinomatosis Index (PCI) tare da hoto da laparoscopy na bincike.
- Peritoneal carcinomatosis daga ciwon daji na hanji, ciwon daji na appendix (ciki har da pseudomyxoma peritonei), ciwon daji na ovary, ko wasu ciwon daji na ciki, a kan Cleveland Clinic da NCBI/StatPearls
- Peritoneal Carcinomatosis Index da yaduwar cutar da aka tantance ta hoton CT/PET da laparoscopy na tantancewa a matsayin mai dacewa da cytoreduction cikakke ko kusan cikakke
- Babu ciwon daji mai muhimmanci a wajen ciki (metastasis na wajen ciki), wanda yawanci zai sa CRS-HIPEC bata dace ba
- Lafiya gaba daya — ciki har da sauran cututtuka da yanayin aiki — mai isa don jure tiyata mai tsawo da farfadowa mai tsawo, wanda kwamitin oncology na tiyata na fannoni daban-daban ya bita
Tsari: Mataki Bayan Mataki
Ana yin CRS-HIPEC a matakai biyu da suka hade a tiyata daya. Matakan da ke kasa sun bayyana hanyar bude ta yau da kullun; hanyar da robot ke taimakawa na iya dacewa da lamura da an zaba a hankali na karancin nauyin ciwon daji (duba kwatancen na yau da kullun da na robot a kasa).
Tantancewa da aikin kafin tiyata
Hoton CT/PET da, a mafi yawan lokuta, laparoscopy na tantancewa suna tabbatar da yaduwar cutar peritoneal kuma suna lissafta Peritoneal Carcinomatosis Index, a kan NCBI/StatPearls.
Tiyatar cytoreductive (CRS)
Tawagar tiyata tana cire duk ciwon daji mai ganuwa daga saman peritoneal kuma, inda aka shafa, gabobin da suka shafi — wannan mataki shi kadai zai iya daukar sa'o'i da yawa dangane da yaduwar cutar.
Chemotherapy ta intraperitoneal mai zafi (HIPEC)
Ana kewaya maganin chemotherapy mai zafi kai tsaye ta cikin ciki na wani lokaci nan take bayan cytoreduction, don magance ragowar cutar kanana wanda tiyata ba za ta iya cirewa ba, a kan Cleveland Clinic.
Rufewa da farfadowa a ICU
Ana rufe ciki kuma ana kai ku zuwa kulawa mai zurfi don sa ido na kusa, saboda yawan tiyata da canje-canjen ruwa da na metabolism da suka shafi.
Jadawalin Farfadowa
CRS-HIPEC na bude yawanci yana daukar sa'o'i masu yawa a dakin tiyata — jerin da aka ruwaito sun bambanta daga kusan sa'o'i 6 zuwa sa'o'i 12-15 dangane da yawan saman peritoneal da ake bukatar magancewa.
Wani lokaci a kulawa mai zurfi yana biye da tiyata don sa ido na kusa na daidaiton ruwa, aikin koda, da matsalolin farko, a kan Cleveland Clinic.
Farfadowa a asibiti yawanci kwanaki 10-14 ko fiye, dangane da yawan tiyata da duk matsaloli, a kan NCBI/StatPearls.
Farfadowa cikakke a gida na ci gaba na wasu makonni; tawagar kula da lafiyar ku za ta shiryar ku kan matakan aiki, abinci mai gina jiki, da hoton bibiya.
Tushen: Cleveland Clinic; Mayo Clinic; NCBI/StatPearls (Bookshelf NBK570563). Farfadowa ta mutum daya na bambanta kuma tawagar oncology ta tiyata ce take shiryar da ita.
Hadura da Iyaka Da Aka Sani
- Zubar anastomotic — karyewar hadin hanji da aka yi a lokacin tiyata — hadari ne da aka sani, kuma yiwuwarsa yana karuwa da yawan cirewar hanji da aka yi, a kan bincike na sakamakon perioperative da aka buga.
- Kamuwa da cuta, ciki har da kamuwa da cuta mai zurfi na wurin tiyata, da bukatar yiwuwar sake tiyata su ma hadura ne da suke karuwa da cirewa mai yawa na hanji.
- Lalacewar koda sanadin chemotherapy na iya faruwa daga maganin da ake kewayawa a lokacin matakin HIPEC kuma ana sa ido a kansa sosai a lokacin da bayan tiyata.
- A matsayin babbar tiyatar ciki, zubar jini da matsalolin gaba daya na tiyata suna kama da sauran manyan hanyoyin oncology na tiyata, a kan NCBI/StatPearls; wani bincike na yanzu ya ruwaito babu mutuwar tiyata ko ta kwana 30, tare da mutuwar kwana 60 ta kashi 2.7%.
- Kamar duk wani tsari da ya shafi maganin sa barci, akwai hadurra da suka shafi maganin sa barci wadanda tawagar likitocin ku za ta yi bita da ku daya-daya.
Tushen: NCBI/StatPearls (Cytoreduction and HIPEC, Bookshelf NBK570563); Cleveland Clinic; bincike na sakamakon perioperative da aka buga (PMC). Babu tsari da bata da hadari; tawagar oncology ta tiyata za ta yi bita da abubuwan hadarin ku daya-daya.
Hanyar Kula da Lafiya ta CureSureMedico
Bitar shari'a daga nesa
Raba hoto, ilimin cuta, da sakamakon laparoscopy na tantancewa. Tawagar tsari-tsarinmu tana kai shari'ar ku ga kwamitin oncology na tiyata don tabbatar da cancanta da lissafta Peritoneal Carcinomatosis Index ku.
Tabbatar da hanya
Kwamitin yana tabbatar ko CRS-HIPEC na bude ko, don cutar mai karancin nauyi da an zaba a hankali, hanyar da robot ke taimakawa ta dace da shari'ar ku.
Kimar da aka hade
Ana bayar da kimar tsada da ta shafi tiyata, maganin chemotherapy na HIPEC, zaman ICU da asibiti, da bibiya na farko kafin ku tafi.
Tiyata da farfadowa mai tsawo
Tawagar kula da lafiyar ku tana sa ido a farfadowar ku ta ICU da asibiti, tana daidaita taimakon abinci mai gina jiki da duk bukatun kula da stoma kafin ku samu izinin tafiya gida.
Cigaba da kulawa bayan dawowa
Ana raba takaitaccen bayani game da magani — ciki har da abubuwan da tiyata ta gano, maganin chemotherapy da aka yi amfani da su, da jadawalin hoton sa ido na bibiya — tare da likitan oncology na gida.
Hanyoyin Magani
Hanya ta Yau da kullum da ta Robot HIPEC / CRS-HIPEC (Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy)
Hanya ta Yau da Kullum
CRS-HIPEC na Bude
21–45 kwanaki
Zaɓin da ke Amfani da Robot
CRS-HIPEC Mai Amfani da Robot
14–28 kwanaki
Kwatanta hanyoyin biyu
| Ta Yau da Kullum | Mai Amfani da Robot | |
|---|---|---|
| Hanyar Magani | CRS-HIPEC na Bude | CRS-HIPEC Mai Amfani da Robot |
| Fasaha | Kayan aikin fiɗa na yau da kullum | Tsarin fiɗa mai amfani da robot ƙarƙashin kulawar likitan fiɗa |
| Samuwa | Ya danganta da asibiti | Zaɓaɓɓun asibitoci masu ikon robot |
| Kwararre | Kwararre kan hanyar magani | Kwararre mai gogewa a kan robot |
| Dacewa ta Asibiti | Ya danganta da yanayin majinyaci | Ya danganta da yanayin majinyaci |
| Farashi | $15,000–$45,000 | $28,000–$50,000 |
| Tsawon Lokaci | 21–45 kwanaki | 14–28 kwanaki |
Cancantar samun magani mai amfani da robot
- Karancin nauyin ciwon peritoneal (Peritoneal Carcinomatosis Index kadan) da an tabbatar da shi ta hoto da laparoscopy na tantancewa — wannan kwatancen ya shafi kawai lamura da an zaba a hankali na karancin nauyi, wanda aka kafa musamman ga ciwace-ciwacen appendiceal kuma an yi nazari a kansa domin cutar kansar ciki mai metastasis kadan a gwaje-gwaje kamar binciken ROBO-CHIP Phase II na Mayo Clinic
- Babu yaduwar cutar peritoneal mai yawa a sassa da yawa wanda zai bukaci samun dama mai fadi na tiyata wanda kawai tiyatar bude za ta iya bayarwa domin cytoreduction cikakke
- Bitar kwamitin oncology na tiyata na fannoni daban-daban wanda ya tabbatar cewa ana iya samun cytoreduction cikakke ko kusan cikakke ta hanyar udanganyifu kadan
- Samuwar dandalin tiyata na robot da tawagar oncology ta tiyata mai kwarewa musamman a CRS-HIPEC ta robot a asibitin da aka zaba — ana bayarwa a asibitoci kadan sosai a duniya
Haɗari da iyakoki na fiɗa mai amfani da robot
- Amfani da robot baya kawar da hadarin CRS-HIPEC, ciki har da zubar anastomotic, zubar jini, kamuwa da cuta, da lalacewar koda sanadin chemotherapy
- Likitan oncology na tiyata shine ke da alhakin samun cytoreduction cikakke; amfani da robot taimako ne, ba madadin hukuncin likitan tiyata ba, kuma sauya zuwa tiyatar bude yana yiwuwa idan cutar ta fi yawa fiye da yadda ake tsammani
- CRS-HIPEC ta robot har yanzu hanya ce mai tasowa da ake nazarin ta galibi a gwaje-gwajen Phase II da jerin bincike na baya domin cutar mai karancin nauyi — tiyatar bude ta kasance daidaitacciyar hanyar kula ga marasa lafiya da yawa, musamman wadanda ke da cutar da ta fi yawa ko a sassa da yawa
- An iyakance samuwa zuwa cibiyoyin oncology na tiyata kadan na musamman, kuma kudin fasaha yana kara farashin gaba daya idan an kwatanta da CRS-HIPEC na bude
Tsarin Farashi
Me ya sa hanyoyin da ke amfani da robot za su iya tsada?
Hanyoyin da ke amfani da robot suna dogaro da ƙarin fasaha da kayan aiki fiye da dandalin fiɗa na yau da kullum da tawagar asibiti. Wannan ƙarin sashin fasaha yawanci ba a haɗa shi cikin farashin yau da kullum ba.
Shin ana ba da shawarar fiɗa mai amfani da robot koyaushe?
A'a. Fiɗa mai amfani da robot ba ta dace da kowace hanyar magani ko majinyaci ba. Samuwa da dacewa ana tantance su ta kwararren da ke kula da magani, bisa hoton likitanci, yanayin lafiyar ku, da ikon asibitin da ake kula da ku.
Kwatancen farashi na duniya — HIPEC / CRS-HIPEC (Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy)
Matsakaicin farashi da aka tsara a fadin cibiyoyinmu na hadin gwiwa. Farashin karshe ya danganta da tsananin yanayi da asibitin da aka zaba.
| Kasa | Matsakaicin farashi | idan aka kwatanta da mafi araha |
|---|---|---|
🇮🇳 India New Delhi · Chennai · Bengaluru · Hyderabad · Mumbai · Kochi | $18,000 | —chevron_right |
🇹🇷 Turkey Istanbul | $32,000 | +78%chevron_right |
Farashi kimantawa ne kuma yana bambanta bisa ga cikakkun bayanan aikin, asibiti, da tsananin yanayin likita. Nemi kimar musamman don al'amarinku.
Tambayoyin da ake yawan yi
Candidacy depends on the extent and location of peritoneal disease, measured using the Peritoneal Carcinomatosis Index (PCI), and whether complete or near-complete cytoreduction is achievable. Patients with peritoneal spread from colorectal cancer, appendiceal cancer (including pseudomyxoma peritonei), ovarian cancer, or select gastric cancers may be candidates, provided there is no extensive disease outside the abdominal cavity and the patient's overall fitness can tolerate a long operation. A multidisciplinary tumour board reviews imaging and staging laparoscopy findings before confirming candidacy.
Babu kudi. Babu alkawari.
Jagoranmu kyauta ne gaba daya
Asibitocinmu na hadin gwiwa ne suke biyanmu — ba majinyata ba. Kuna samun daidaita likitanci mai zaman kansa, bayyana farashi, da cikakken tsari ba tare da kudi a kanku ba.